Nov 14, 2024 9:15am EST ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
Nov 12, 2024 7:00am EST ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
Oct 30, 2024 8:00am EDT ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
Sep 12, 2024 7:00am EDT ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
Sep 05, 2024 7:00am EDT ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Aug 08, 2024 7:00am EDT ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights
Aug 06, 2024 7:00am EDT ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology
Aug 01, 2024 7:00am EDT ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
Jul 30, 2024 8:30am EDT ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
Jul 26, 2024 8:35am EDT ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial